CGON
CG Oncology Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +30.0% ·
net new positions +11.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | +7 | 45.64M | $3.24B | +12 | −5 |
| Q1 2026 | 90 | +11 | 42.64M | $2.85B | +15 | −4 |
| Q4 2025 | 77 | 0 | 47.85M | $1.99B | — | — |
| Q3 2025 | 16 | 0 | 30.32M | $1.22B | +1 | −1 |
| Q2 2025 | 13 | +1 | 24.41M | $634.75M | +2 | −1 |
| Q1 2025 | 9 | 0 | 12.23M | $299.43M | +1 | −1 |
| Q4 2024 | 9 | +1 | 9.32M | $267.32M | +1 | — |
| Q3 2024 | 7 | -2 | 3.66M | $137.92M | — | −2 |
| Q2 2024 | 9 | — | 2.48M | $78.32M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.92M | — | $55.17M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.91M | +274.4% | $54.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 1.46M | +18836.0% | $41.82M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.17M | +263.8% | $33.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.17M | +263.8% | $33.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 1.16M | +7.2% | $33.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 1.16M | +7.2% | $33.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 945.19K | +59.8% | $27.11M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 945.19K | +59.8% | $27.11M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 308.26K | -58.7% | $8.84M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Millennium Management ✦ | 249.00K | New | $7.14M | 0.0% | New | 1 | SEC ↗ |
| 17 | Adage Capital Partners ✦ | 200.00K | -50.0% | $5.74M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $7.14M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 232 holders, 86.28M shares, $5.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 1.00K sh · $74,540
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology